Validation and modification of HPLC method for monitoring acetaminophen plasma concentrations in patients with chronic pancreatitis - Publikacja - MOST Wiedzy

Wyszukiwarka

Validation and modification of HPLC method for monitoring acetaminophen plasma concentrations in patients with chronic pancreatitis

Abstrakt

Background.

Pancreatitis is the inflammation of the pancreas. The infl ammation may occur suddenly and resolve in a few days with the treatment in case of acute pancreatitis (AP). Chronic pancreatitis (CP) is a persistent inflammation of the pancreas that results in irreversible morphological changes and impairment of both exocrine and endocrine functions. Abdominal pain is a typical symptom in both acute and chronic pancreatitis. Therefore, the application of analgesics to this group of patients is a part of complex pharmacotherapy.

Material and methods. 
A simple, precise, specific, and accurate HPLC (High Performance Liquid Chromatography) method was developed 
for the determination of acetaminophen (AAP) in human plasma. The chromatography was set on XTerra® RP C18, 150×4.6 mm, 3.5 μm column. The UV detector was set at 254 nm for AAP and phenacetin (internal standard). The injection volume was 2 μL. The mobile phase comprised phosphate buffer pH 3.5 and methanol in the ratio of 80:20 with flow rate of 1 mL/min.

Results.

The calibration for AAP was linear in the range 1.0-30.0 μg/mL. Lower limit of quantifi cation (LLOQ) was 1.0 μg/mL. The results for quality control samples (QCs) at concentrations of 1, 6, 15, and 25 μg/mL were less than 15% indicating good intra- and inter-day precision. Blood samples from patients with chronic pancreatitis were collected within 8 h aft er the drug intravenous administration (1000 mg). Pharmacokinetic (PK) parameters for AAP were estimated by non-compartmental method.

Conclusion.

The proposed HPLC-UV method is suitable for routine analysis in patients. (Farm Współ 2017; 10: 3-10)

Cytuj jako

Pełna treść

pobierz publikację
pobrano 17 razy
Wersja publikacji
Accepted albo Published Version
Licencja
Creative Commons: CC-BY-NC-ND otwiera się w nowej karcie

Słowa kluczowe

Informacje szczegółowe

Kategoria:
Publikacja w czasopiśmie
Typ:
Publikacja w czasopiśmie
Opublikowano w:
Farmacja Współczesna nr 10, wydanie 1, strony 3 - 10,
ISSN: 1899-2293
Rok wydania:
2017
Bibliografia: test
  1. National Digestive Diseases Information Clearinghouse NIH Publication, July 2008;08-1596. otwiera się w nowej karcie
  2. Nair RJ, Lawrel LB, Miller MR. Chronic Pancreatitis. Am Family Physician. 2007;76(11):1679-88.
  3. Warshaw AL, Banks PA, Fernandez-Del Castillo C. AGA technical review: treatment of pain in chronic pancreatitis. Gastroenterology. 1998;115:765-76. otwiera się w nowej karcie
  4. Yadav D, Lowenfels AB. Th e epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013; 144(6):1252-61. otwiera się w nowej karcie
  5. Lin Y, Tamakoshi A, Matsuno S, et al. Nationwide epidemiological survey of chronic pancreatitis in Japan. J Gastroenterol. 2000;35:136- 41. otwiera się w nowej karcie
  6. Chen WX, Zhang WF, Li B, et al. Clinical manifestations of patients with chronic pancreatitis. Hepatobiliary Pancreat Dis Int. 2006;5:133- 7.
  7. Tenner S, Baillie J, DeWitt J, et al. Management of Acute Pancreatitis. Am J Gastroenterol advance online publication 2013;108(9):1400- 15. otwiera się w nowej karcie
  8. Govt. of India, Ministry of Health and Family Welfare. Vol. 2. Delhi: Publication by Controller of Publication; 1996. Indian Pharmacopoeia; pp. 484-554.
  9. Bonnefont J, Courade JP, Alloui A, et al. Antinociceptive mechanism of action of paracetamol. Drugs. 2003; 63: 1-4. otwiera się w nowej karcie
  10. Vane JR, Botting RM. Th e history of anti-infl ammatory drugs and their mechanism of action. In: Bazan N, Botting J, Vane J, editors. New targets in infl ammation: inhibitors of COX-2 or adhesion molecules. Dordrecht: Kluwer Academic; 1996. p. 1-12. otwiera się w nowej karcie
  11. AFT Pharmaceuticals Pty Ltd. PARACETAMOL-AFT. 2013;6: 3. otwiera się w nowej karcie
  12. Forrest JA, Clements JA, Prescott LF, Clinical Pharmacokinetics of Paracetamol. Clin Pharmacokinet. 1982;7(2):93-107. otwiera się w nowej karcie
  13. Burton M, Shaw L, Schentag J, Evans W. Applied Pharmacokinetics & Pharmacodynamics: Principles of Th erapeutic Drug Monitoring 2006:4:754.
  14. Hinchman CA, Nazzareno B. Glutathione Conjugation and Conversion to Mercapturic Acids Can Occur as an Intrahepatic Process. J Toxicol Environ Health. 1994;41(4):387-409. otwiera się w nowej karcie
  15. Peery AE, Dellon ES, Lund J, et al. Burden of gastrointestinal diseases in the United States: 2012 Update. Gastroenterology. 2012;143:1179- 87. otwiera się w nowej karcie
  16. Fagenholz PJ, Fernandez-del Castillo C, Harris NS,, et al. Direct medical costs of acute pancreatitis hospitalizations in the United States. Pancreas. 2007;35:302-7. otwiera się w nowej karcie
  17. Olesen AE, Brokjaer A, Fisher I, et al. Pharmacological challenges in chronic pancreatitis. World J Gastroenterol. 2013;19(42):7302-7. otwiera się w nowej karcie
  18. Hammer HF. Pancreatic exocrine insuffi ciency: diagnostic evaluation and replacement therapy with pancreatic enzymes. Dig Dis. 2010;28(2):339-43. otwiera się w nowej karcie
  19. Forsmark CE. Chronic pancreatitis and malabsorption. Am J Gastroenterol. 2004;99(7):1355-7. otwiera się w nowej karcie
  20. Helmy SA, El-Bedaiwy HM. Simultaneous Determination of Paracetamol and Methocarbamol in Human Plasma By HLPC Using UV Detection with Time Programming: Application to pharmacokinetic Study. Drug Res. 2014;64:363-7. otwiera się w nowej karcie
  21. Paparoupa M, Pietrzak S, Gillissen A. Case Report Acute Rhabdomyolysis Associated with Coadministration of Levofl oxacin and Simvastatin in a Patient with Normal Renal Function. Case Rep Med. 2014;2014:1-4. otwiera się w nowej karcie
  22. Mythen M, Burdett E, Stephens R. Assessment of Renal Functional: Radiological. Anaesthesiology: Churchill›s Ready Reference, Elsevier Health Sciences, 2010;106-107.
  23. European Medicine Agency: science medicines health Guideline on bioanalytical method validation, 21 July 2011 EMEA/CHMP/ EWP/192217/2009 Rev.1 Corr. Committee for Medicinal Products for Human Use (CHMP). Retrieved Januray 8, 2017, from http://www. ema.europa.eu/docs/en_GB/document_library/Scientifi c_guideline /2011/08/WC500109686.pdf. otwiera się w nowej karcie
  24. Ji, Suresh D, Yaning W. Clinical Pharmacology and Biopharmaceutics Review(S) Center For Drug Evaluation and Research. 2009; 022450Orig1s000: 4. otwiera się w nowej karcie
Weryfikacja:
Brak weryfikacji

wyświetlono 41 razy

Publikacje, które mogą cię zainteresować

Meta Tagi